Patient-Reported Satisfaction With An Extended Depth Of Focus Intraocular Lens: A Meta-Analysis
Published 2023 - 41st Congress of the ESCRS
Reference: PO0520 | DOI: 10.82333/r37t-xy76
Authors: Jesse Vislisel 1 , Jun Zhang* 2 , Mukesh Dhariwal 2
1Associated Eye Care,Stillwater, Minnesota,United States, 2Alcon,Fort Worth, Texas,United States
AcrySof IQ Vivity (DFTXXX/DATXXX) is an extended depth of focus (EDOF) IOL that uses novel non-diffractive X-WAVE technology to restore visual performance in cataract patients. A proportional meta-analysis of recently published evidence was conducted to evaluate the patient-reported satisfaction after bilateral implantation of DFTXXX/DATXXX IOL.
Global literature review
PubMed and the congress abstract databases ( AAO, APACRS, APAO, ASCRS and ESCRS) were searched from April 2021 to December 2022. Eight studies (6 peer-reviewed and 2 congress publications) reporting patient satisfaction with DFTXXX/DATXXX IOL were included in this review. Other inclusion criteria were bilateral implantation, patient-reported, randomized or observational studies, and final data/results reporting follow-up of 1 or more months. Fixed and random effects meta-analyses were conducted for outcomes related to patient satisfaction (satisfied or very satisfied) with a 95% confidence interval [CI]. The “meta” package of R software was used to conduct the meta-analysis.
Seven prospective studies (1 non-interventional controlled, multicenter; 1 open-label, multicenter; 1 non-comparative case series; 1 single arm unmasked, 1 observational; 2 case-control) and one ambispective registry were found in this review. The studies included 903 patients from 11 different countries with a follow-up period ranging from 1 month to >12 months. Patient satisfaction was obtained from the PRO (n=1), PRSIQ (n=1), 23-question survey on visual performance (n=1), CATQUEST-9SF (n=3), and unreported questionnaires (n=2). According to random effects meta-analysis, 94.9% [95% CI: 90.8 – 98.1%] of patients were satisfied with DFTXXX/DATXXX IOL implantation.
This meta-analysis of recent scientific and congress publications reveals high rates of patients reporting satisfaction with bilateral implantation of DFTXXX/DATXXX EDOF IOL. These results help patients and providers make informed decisions when selecting an IOL for cataract surgery.